Viewpoint Molecular Targeting™ Chief Scientific Officer, Dr. Michael Schultz, Discusses the Promise of Image-Guided 212Pb Alpha-Particle Radiopharmaceutical Therapies for Cancer at the SNMMI 2021 Annual Meeting

– Presented data highlights the performance of Viewpoint’s chelation technology –   Coralville, IA, June 15, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle...